West Lake Vitek
Saliva-based diagnostics for early oral cancer detection.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | N/A | CNY20.0m | Early VC |
| Total Funding | 000k | ||
West Lake Vitek is a biotechnology company focused on developing non-invasive, saliva-based diagnostic tools for the early detection of oral cancer. The company's core technology aims to identify specific protein-based biomarkers that are overexpressed when oral lesions become malignant. This approach is designed to provide a more accurate and objective risk assessment compared to traditional screening methods like visual examinations, which can miss subtle or subsurface malignancies.
The firm's flagship product, the BeVigilant™ OraFusion™ System, is an FDA-designated breakthrough device. It functions as a point-of-care, chairside risk assessment tool that provides results in approximately 15 minutes. The system integrates the analysis of two key salivary biomarkers with a software-driven evaluation of clinical risk factors, including a patient's age, sex, race, and history of alcohol and tobacco use. This dual analysis generates a result of "low," "moderate," or "elevated" risk for oral cancer with a reported sensitivity and specificity of over 90%. By offering rapid and precise information, the system empowers clinicians to make more informed decisions about patient referrals and follow-up care, facilitating diagnosis at earlier, more treatable stages (Stages I and II).
The business model centers on providing these diagnostic systems to clinicians, enabling seamless integration into standard clinical workflows. The market for this technology includes dental practices and other healthcare settings where oral cancer screenings are performed. By enabling earlier detection, West Lake Vitek aims to improve patient survival rates, which are estimated to be as high as 80-90% with early diagnosis, and reduce the need for extensive and costly late-stage treatments.
Keywords: oral cancer diagnostics, saliva-based testing, point-of-care diagnostics, early cancer detection, salivary biomarkers, non-invasive diagnostics, medtech, oral oncology, BeVigilant OraFusion System, oral lesion screening, preventative healthcare, dental technology, clinical risk assessment, immunoassay, molecular diagnostics, head and neck cancer, diagnostic devices, life sciences